Normative Diffusion Autoencoders: Application to Amyotrophic Lateral Sclerosis

Predicting survival in Amyotrophic Lateral Sclerosis (ALS) is a challenging task. Magnetic resonance imaging (MRI) data provide in vivo insight into brain health, but the low prevalence of the condition and resultant data scarcity limit training set sizes for prediction models. Survival models are further hindered by the subtle and often highly localised profile of ALS-related neurodegeneration. Normative models present a solution as they increase statistical power by leveraging large healthy cohorts. Separately, diffusion models excel in capturing the semantics embedded within images including subtle signs of accelerated brain ageing, which may help predict survival in ALS. Here, we combine the benefits of generative and normative modelling by introducing the normative diffusion autoencoder framework. To our knowledge, this is the first use of normative modelling within a diffusion autoencoder, as well as the first application of normative modelling to ALS. Our approach outperforms generative and non-generative normative modelling benchmarks in ALS prognostication, demonstrating enhanced predictive accuracy in the context of ALS survival prediction and normative modelling in general.

Semi-Supervised Diffusion Model for Brain Age Prediction

Brain age prediction models have succeeded in predicting clinical outcomes in neurodegenerative diseases, but can struggle with tasks involving faster progressing diseases and low quality data. To enhance their performance, we employ a semi-supervised diffusion model, obtaining a 0.83(p<0.01) correlation between chronological and predicted age on low quality T1w MR images. This was competitive with state-of-the-art non-generative methods. Furthermore, the predictions produced by our model were significantly associated with survival length (r=0.24, p<0.05) in Amyotrophic Lateral Sclerosis. Thus, our approach demonstrates the value of diffusion-based architectures for the task of brain age prediction.